Showing results (31-40 of 400) with videos related to

Sort By:
Pageof 40
Seminars in Thrombosis and Hemostasis|April 1, 1991
Comparative studies on various assays for the laboratory evaluation of r-hirudinJ M Walenga, D Hoppensteadt, M Koza, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1991
An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agentJ Fareed, J M Walenga, L Iyer, et al.
Haemostasis|January 1, 1986
Laboratory studies on the intravenous and subcutaneous administration of PK 10169 in manJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Thrombosis Research|December 15, 1988
Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activityJ M Walenga, M Petitou, M Samama, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1996
Are the available low-molecular-weight heparin preparations the same?J Fareed, W Jeske, D Hoppensteadt, et al.
The Canadian Journal of Cardiology|October 21, 1998
Low molecular weight heparins: are they different?J Fareed, D Hoppensteadt, W Jeske, et al.
Critical Reviews in Clinical Laboratory Sciences|January 1, 1983
Synthetic peptide substrates in hemostatic testingJ Fareed, H L Messmore, J M Walenga, et al.
Haemostasis|January 1, 1991
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudinJ Fareed, J M Walenga, R Pifarre, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1985
A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractionsJ Fareed, A Kumar, A Rock, et al.
Mediators of Inflammation|January 1, 1993
Heparan sulphate inhibition of cell proliferation induced by TGFbeta and PDGFL E Silber, J M Walenga, J Fareed, et al.
Pageof 40